[Alert] Buy Havas
Havas is a recent spin-off from Vivendi. Havas delivered record financial results in 2024, with net revenue of €2,736 million (+1.5% y/y) and all...
84 Views
US Tariff Impact Estimates
New US tariffs ignored any notion of reciprocity, reaching shockingly substantial sizes. However, the UK was relatively fortunate in landing on...
238 Views
South African Listed Property Review - March 2025
The first quarter of 2025 was an immensely challenging month, SA listed property was down by -4.12% for the quarter, and it certainly does not look...
143 Views
ECB Meeting Accounts - March 2025
In the accounts for its March meeting, the ECB cited a broadly intact disinflation path and moderating wage pressures, but emphasised that rising...
160 Views
OSE Immunotherapeutics — Primed for value appreciation
OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The...
158 Views